EXCELLENCIA
INTERNATIONAL MULTI-DISCIPLINARY JOURNAL OF EDUCATION
Volume 3, Issue 2, 2025 ISSN (E): 2994-9521

The Role of Microbiota in the Pathogenesis of Pregnancy Complications

L. R. Agababyan[1], Khurramova F. B.[2], Ravshanova S.[3]

Abstract:

Human microbiota plays a crucial role in maintaining health, including during pregnancy, when changes in microbiota composition can affect pregnancy outcomes and contribute to complications. Studies indicate that microbiota imbalances, including vaginal and gut microbiota, are associated with conditions such as preeclampsia, gestational diabetes, urinary tract infections, preterm birth, and other obstetric pathologies. The influence of microbiota on immune, metabolic, and inflammatory regulation can significantly affect maternal and fetal health. The primary methods for correcting microbiota disturbances in pregnant women include probiotics, dietary therapy, and antibiotics. Maintaining a healthy microbiota composition through diet and probiotics helps prevent infectious and inflammatory complications, thereby supporting normal pregnancy progression.

Keywords: Microbiota, pregnancy, preeclampsia, gestational diabetes, urinary tract infections, probiotics, dietary therapy, dysbiosis, inflammation, immune response.

Introduction

The study of microbiota and its role in pregnancy complications is a rapidly evolving field with significant implications for maternal and fetal health. The human microbiota, particularly the vaginal and gut microbiomes, plays a crucial role in maintaining homeostasis, regulating immune function, and preventing infections. However, pregnancy induces hormonal, metabolic, and immunological changes that can alter microbiota composition, potentially increasing susceptibility to complications such as **preeclampsia, gestational diabetes, urinary tract infections, and preterm birth**.

Method

Recent studies suggest that dysbiosis, or an imbalance in microbial communities, may contribute to systemic inflammation, insulin resistance, and immune dysfunction, all of which can negatively

affect pregnancy outcomes. The growing prevalence of pregnancy-related complications necessitates a deeper understanding of microbiota dynamics and their interaction with maternal health.

With increasing evidence supporting the role of microbiota in obstetric pathology, interventions such as probiotics, dietary modifications, and targeted antimicrobial therapy are being explored as potential strategies for preventing and managing pregnancy complications. However, there is still a lack of consensus regarding the optimal methods, dosages, and long-term effects of microbiota-modulating interventions.

Given the high global burden of maternal and neonatal morbidity and mortality associated with pregnancy complications, further research into microbiota-based therapeutic approaches is essential. Understanding the precise mechanisms linking microbiota dysbiosis to adverse pregnancy outcomes will help develop personalized strategies for maternal health improvement, ultimately reducing obstetric risks and enhancing neonatal well-being.

Human microbiota consists of a complex community of microorganisms that exist in symbiosis with the host, maintaining homeostasis in the body. During pregnancy, significant changes occur in vaginal and gut microbiota due to hormonal and immune shifts. For example, the first trimester is characterized by an increase in lactobacilli in the vagina, providing protection against infections such as bacterial vaginosis and candidiasis [8]. Changes in gut microbiota composition can influence inflammatory responses and metabolism, which, in turn, may impact pregnancy progression and the development of complications [12].

In recent years, interest in studying the role of microbiota in various diseases and pregnancy complications has grown significantly. As a collective of microorganisms inhabiting different systems of the human body (including the gut, vagina, and respiratory tract), microbiota influences immune, metabolic, and inflammatory regulation, which is crucial during pregnancy. The impact of microbiota on maternal and fetal health has been extensively studied, revealing associations between microbiota disturbances and complications such as preeclampsia, gestational diabetes, preterm birth, and infections.

Microbiota and Immune Response During Pregnancy

The female immune system undergoes significant changes during pregnancy to adapt to the presence of the fetus and prevent its rejection. However, these changes can also increase susceptibility to infections and inflammatory processes. Research shows that microbiota plays a key role in regulating both innate and adaptive immune responses. Microbiota imbalance, or dysbiosis, can lead to chronic inflammation and disrupted immune regulation, increasing the risk of conditions such as preeclampsia.

Some studies suggest that reduced gut microbiota diversity can trigger inflammatory cascades, contributing to preeclampsia development. The pathogenic role of microbiota lies in activating immune cells such as T-lymphocytes and macrophages, which promote inflammation and can influence hypertension and vascular endothelial damage (Bäckhed et al., 2015).

Result and Discussion

Several studies have demonstrated that gut microbiota diversity is directly linked to immune cell functions, such as those of T-lymphocytes and macrophages. An imbalance in this system can result in chronic inflammation, which in turn contributes to cardiovascular conditions such as preeclampsia (Bäckhed et al., 2015). Pregnancy-related hormonal, immune, and metabolic changes also affect the microbiome. Research highlights that vaginal microbiota plays a crucial role in maintaining a normal microbial ecosystem, helping to prevent infections such as bacterial vaginosis

and candidiasis. Additionally, gut microbiota influences inflammation, immune reactivity, and metabolism, potentially affecting pregnancy outcomes.

Microbiota and Obstetric Pathologies

Accumulated data indicate a link between microbiota disturbances and various obstetric complications.

- Vaginal dysbiosis, characterized by a decrease in lactobacilli and an increase in anaerobic bacteria, has been associated with a higher risk of preterm birth. The primary factor is the disruption of microbiota's barrier function, leading to inflammatory processes and infections [8;12].
- Vaginal microbiota imbalance can increase susceptibility to urinary tract infections, such as cystitis, which is particularly concerning during pregnancy [2;16].
- Gut microbiota disturbances have been linked to preeclampsia due to their influence on immune response and inflammatory mechanisms. Reduced microbiota diversity and imbalances between Gram-positive and Gram-negative microorganisms may contribute to systemic inflammation and preeclampsia development [10].
- Some studies highlight the role of gut microbiota in the pathogenesis of gestational diabetes. A reduction in Bifidobacteria and an increase in Firmicutes, among other microbiome changes, may be associated with insulin resistance and metabolic disorders during pregnancy [12;14].

Correction of Microbiota Disorders in Pregnant Women

Microbiota imbalances in pregnant women are primarily corrected using probiotics, dietary therapy, and, in some cases, antibiotics.

Probiotics. The use of probiotics during pregnancy has been shown to be effective in restoring vaginal and gut microbiota balance. Probiotics containing Lactobacilli and Bifidobacteria positively impact microbiota restoration, suppression of pathogenic microorganisms, and improved immune function. Some studies confirm that probiotics can reduce the incidence of urinary tract infections and bacterial vaginosis in pregnant women [9;13].

Dietary Therapy. Nutrition plays a key role in microbiota regulation. Fiber-rich foods, probiotic cultures (e.g., kefir and yogurt), and reduced sugar and fat intake contribute to gut and vaginal microbiota health [2;5]. A diet aimed at microbiota balance is an essential part of pregnancy complication prevention.

Antibiotics. When infections require antibiotic therapy, minimizing treatment duration and frequency is crucial to prevent microbiota deterioration. However, in severe infections, antibiotics play a vital role, particularly in treating urinary tract infections or bacterial vaginosis, which can lead to pregnancy complications [6;17].

Fecal Microbiota Transplantation (FMT). FMT is an innovative method used to restore gut microbiota in cases of severe dysbiosis resistant to conventional treatment. However, its application in obstetrics requires further research and safety evaluations for pregnant women [15;16].

Future Perspectives and Challenges

The late 20th and early 21st centuries have seen the development of numerous probiotic supplements for the human body, particularly for women. Advances in technology allow for modulating both the quantity and combination of microorganisms, as well as their delivery methods. Given the increasing recognition of the gut microbiome's role in maternal and neonatal health, microbiome modulation presents an intriguing avenue for disease prevention. This has led to a rise in prebiotic and probiotic interventions aimed at preventing pregnancy complications and

optimizing infant health. However, due to study heterogeneity—varying probiotic strains, treatment durations, and conditions examined—systematic evaluations are necessary.

A **2021 Cochrane systematic review** advised caution regarding probiotic use during pregnancy. The review included six studies with a total of 1,440 participants and concluded that the effect of probiotics on gestational diabetes risk remains unclear [3;6]. Additionally, probiotics were found to increase the risk of preeclampsia and had no impact on maternal weight gain. A separate review by Jarde et al. analyzed 19 studies (n = 4,098) and found no conclusive link between probiotic supplementation and improved maternal or neonatal outcomes [11;15].

Despite ongoing debates on probiotic efficacy, studies suggest their potential for **pathogenetic correction of vaginal and gut dysbiosis in pregnant women**, particularly in preventing preterm birth, gestational diabetes, and preeclampsia. Clinical trials indicate that probiotic strains such as *Lactobacillus rhamnosus* GR-1 and *Lactobacillus reuteri* RC-14 are safe and effective at various pregnancy stages [1].

Conclusion

Thus, microbiota correction strategies represent a promising approach to preventing pregnancy complications. However, further well-designed studies and clinical trials are needed to determine optimal probiotic regimens, dosages, and durations.

LITERATURE

1. Агабабян Л. Р., Ахмедова А. Т., Актамова Н. Прогнозирование и профилактика гнойно-септических заболеваний у беременных с заболеваниями полости рта (обзор литературы) //ЖУРНАЛ РЕПРОДУКТИВНОГО ЗДОРОВЬЯ И УРО-НЕФРОЛОГИЧЕСКИХ ИССЛЕДОВАНИЙ. – 2022. – Т. 3. – №. 4.
2. Агабабян Л. Р., Ахмедова А. Т. Возможности коррекции климактерических расстройств у женщин с противопоказанием к заместительной гормональной терапии //Проблемы репродукции. – 2017. – Т. 23. – №. 3. – С. 108-110.
3. Агабабян Л. Р., Насирова З. А. Послеабортный уход-особенности контрацепции //Фундаментальные и прикладные исследования науки XXI века. Шаг в будущее. – 2017. – С. 48-50.
4. Ахмедова А. Т., Шамсиддинова Д., Мирзаева Г. А. ХРОНИЧЕСКАЯ ГИПОХРОМНАЯ АНЕМИЯ ПРИ ПЕРВОЙ БЕРЕМЕННОСТИ-ОСОБЕННОСТИ ТЕЧЕНИЯ //Развитие и инновации в науке. – 2024. – Т. 3. – №. 10. – С. 72-75.
5. Агабабян Л. Р., Гайибов С. С., Носирова З. А. Особенности течения медикаментозного прерывания беременности у женщин с рубцом на матке //International scientific review. – 2017. – №. 2 (33). – С. 102-103.
6. Агабабян Л. Р. и др. Особенности чистопрогестиновой контрацепции у женщин с преэклампсией/эклапмсией //Вопросы науки и образования. – 2019. – №. 26 (75). – С. 70-76.
7. Агабабян Л. Р. и др. Негормональная коррекция климактерических расстройств у женщин с эндометриозом //Вопросы науки и образования. – 2019. – №. 26 (75). – С. 77-84.
8. Ахмедова А. Т., Камалов А. И., Хушбекова Д. ОСОБЕННОСТИ АНЕМИИ У БЕРЕМЕННЫХ ЖЕНЩИН //Miasto Przyszłości. – 2024. – Т. 53. – С. 369-373.
9. Ахмедова А. Т. ОСОБЕННОСТИ ТЕЧЕНИЯ ПЕРВОЙ БЕРЕМЕННОСТИ КОМОРБИДНОЙ С ЖЕЛЕЗОДЕФИЦИТНОЙ АНЕМИЕЙ //International journal of scientific researchers (IJSR) INDEXING. – 2024. – Т. 5. – №. 2. – С. 846-850.

10. Ахмедова А. Т. и др. ОСОБЕННОСТИ АНЕМИИ У ПЕРВОБЕРЕМЕННЫХ //CONFERENCE ON THE ROLE AND IMPORTANCE OF SCIENCE IN THE MODERN WORLD. – 2024. – Т. 1. – №. 1. – С. 156-158.
11. Ахмедова А. Т., Муинова З. М. ПЕРВАЯ БЕРЕМЕННОСТЬ И СОМАТИЧЕСКАЯ КОМОРБИДНОСТЬ //Miasto Przyszłości. – 2024. – Т. 48. – С. 1744-1747.
12. Насирова З. А., Агабабян Л. Р. Постплацентарное введение внутриматочных спиралей у женщин, родоразрешенных абдоминальным путем //Проблемы репродукции. – 2017. – Т. 23. – №. 2. – С. 81-83.
13. Насирова З. А., Агабабян Л. Р. Современные взгляды на эффективность и приемлемость различных методов контрацепции после кесарева сечения //Вестник науки и образования. – 2020. – №. 12-3 (90). – С. 103-109.
14. Nasirova Z. A., Agababyan L. R. Reproductive behavior of women after cesarean section //International scientific review. – 2020. – №. LXX. – С. 88-92.
15. Агабабян Л. Р., Насырова З. А., Орипова Д. Б. Дистанционное наблюдение за беременными в условиях пандемии COVID-19 //Медицинское образование сегодня. – 2020. – Т. 3. – №. 11. – С. 115-25.
16. Jarde A, Lewis-Mikhael A-M, Moayyedi P, Stearns JC, Collins SM, Beyene J, McDonald SD. Pregnancy outcomes in women taking probiotics or prebiotics: a systematic review and meta-analysis. BMC Pregnancy Childbirth. 2018;18(1):14.
17. Koren O, Goodrich JK, Cullender TC, et al. Host remodeling of the gut microbiome and metabolic changes during pregnancy. Cell. 2012;150(3):715-725.
18. Mendling W, Ziklo N, Smith C, et al. Vaginal microbiota and the risk of preterm birth. Eur J Obstet Gynecol Reprod Biol. 2020;246:65-69.
19. Nuriel-Ohayon M, Neuman H, Koren O. Microbial changes during pregnancy, birth, and infancy. Front Microbiol. 2016;7:1031.
20. Vrieze A, Van Nood E, Holleman F, et al. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2018;145(3):573-583.
21. Zhang C, Yang L, Yao J, et al. Gut microbiome changes in pregnancy and the development of gestational diabetes. Front Microbiol. 2020;11:568.
22. Zmora N, Zilberman-Schapira G, Suez J, et al. Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features. Cell. 2018;174(7):1388-1405.e21.